retatrutide phase 2 trial new england journal of medicine approval: FDA status, clinical results, and when it could be available Retatrutide Shows Promising Weight Loss

Based on SURMOUNT-1 data analysis, tirzepatide decreased the 10-year estimated risk of ASCVD for obese or overweight patients

We focus on a holistic approach that addresses not only weight loss but overall wellness, helping you build habits and strategies that will maintain your results for the long term

These calculations are based on a 100-unit insulin syringe where 1 mL equals 100 units

By contrast, countries like India, which do not award patent term extensions, could see generic competition entering much sooner once the patents on the main compound expire there in 2026

A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia